Compounded tirzepatide vs tirzepatide: learn how FDA-approved Zepbound and Mounjaro differ from pharmacy-made versions in approval, dosing, and safety.
Compounded tirzepatide and tirzepatide are not the same product, even when a label lists the same active ingredient. Tirzepatide is the FDA-approved molecule in Mounjaro and Zepbound, while compounded tirzepatide is a pharmacy-made version that the FDA has not approved and has said is not eligible for federal compounding.
That difference affects safety, dosing accuracy, cost, and legal status. Here is how the two compare.
What Is Tirzepatide?
Tirzepatide is a once-weekly injection that activates two hormone receptors, GIP and GLP-1. It is the active ingredient in two FDA-approved brand-name drugs.
- Mounjaro — approved in 2022 to treat type 2 diabetes in adults, used alongside diet and exercise.
- Zepbound — approved in 2023 for chronic weight management in adults who meet specific BMI or health criteria.
Approved tirzepatide is sold as single-dose pens and, for select lower doses, single-dose vials. The manufacturer must follow FDA manufacturing standards, and each dose is fixed so patients do not have to measure it themselves.
What Is Compounded Tirzepatide?
Compounded tirzepatide is prepared by a compounding pharmacy, usually as a multi-dose vial that the patient draws up with a syringe. Some formulas add vitamin B12, glycine, or other ingredients. Compounded drugs are not FDA-approved.
That does not mean every compounded product is unsafe, but it does mean the product has not been reviewed for effectiveness, purity, or correct labeling. FDA sampling of compounded tirzepatide has found potency errors, impurities, and different drug forms than the approved product.
Compounded Tirzepatide vs Tirzepatide: Side-by-Side
| Feature | FDA-approved tirzepatide | Compounded tirzepatide |
|---|---|---|
| FDA approval | Yes, for specific indications | No |
| Active ingredient | Tirzepatide, per the approved label | Tirzepatide base, a salt, or an analog; may include B12 |
| Available forms | Single-dose pens; select vials | Multi-dose vials, prefilled syringes |
| Dosing | Fixed doses from 2.5 mg to 15 mg weekly | Varies by pharmacy; may be listed in "units" |
| Quality oversight | FDA-inspected manufacturing | State pharmacy board oversight; limited testing |
| Typical cost | Often $500–$1,000+ per month without insurance | Often $200–$400 per month |
| Insurance coverage | Covered for some plans and indications | Usually not covered |
FDA Rules, Dosing, and Cost Differences
The FDA removed tirzepatide from its drug shortage list in late 2024 and gave compounding pharmacies deadlines to stop making copies in early 2025. A federal court later allowed that decision to stand. Large-scale compounding of tirzepatide is therefore no longer permitted in the United States.
Some pharmacies still fill patient-specific prescriptions under state rules, so availability varies. State pharmacy boards license compounders, which means the rules are not identical from state to state. If you are offered a compounded product, ask which pharmacy made it and whether the facility is registered as a 503A or 503B operation.
Dosing is not always equivalent
Approved tirzepatide moves from 2.5 mg to 15 mg per week in fixed steps. Compounded vials often use different concentrations and may be labeled in "units" instead of milligrams. That mismatch has contributed to dosing errors, including accidental overdoses.
Purity and labeling can vary
Compounded products are not required to match the approved drug's specifications. Independent testing has found vials with more or less drug than stated, plus impurities that are not present in approved tirzepatide. There is also no guarantee that a vial labeled "tirzepatide" contains only tirzepatide.
Cost is the main reason people switch
Compounded tirzepatide has typically cost less than brand-name pens, but manufacturer self-pay vials have narrowed the gap. Compounded products are usually not covered by insurance, and coupons for Mounjaro or Zepbound do not apply to them.
Safety, Side Effects, and Comparisons
Side effects to watch for
Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents. It is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, and injection-site reactions. Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and low blood sugar when the drug is combined with insulin or sulfonylureas.
Hair thinning is a frequently reported complaint, which is one reason searches for tirzepatide vs semaglutide hair loss have increased. Rapid weight loss itself may contribute to shedding, and reports exist for both drugs.
How tirzepatide compares with other options
Tirzepatide is not the only medication in this category. People researching semaglutide vs tirzepatide weight loss often find that tirzepatide produced slightly greater average weight loss in a head-to-head trial, although individual results vary.
Combination therapies are also in development. Researchers are studying cagrilintide vs tirzepatide and cagrisema vs tirzepatide as potential next-generation treatments, but these products are investigational and not FDA-approved for weight management.
Other injectables sold by some telehealth clinics, such as lipo-c vs tirzepatide, work through completely different mechanisms and are not proven weight-loss drugs.
What to Ask Your Prescriber
- Is the tirzepatide you are prescribing FDA-approved, and which brand is it?
- If it is compounded, which pharmacy makes it and what is the exact strength?
- How should I measure and store the medication?
- Which side effects should make me stop and call you?
- Does my insurance cover an approved version, and what will I pay out of pocket?
No version of tirzepatide is a cure for obesity or diabetes, and both work best alongside nutrition, activity, and regular medical follow-up. Talk with a licensed healthcare professional before starting, switching, or stopping any GLP-1 medication.
Frequently Asked Questions
Is compounded tirzepatide the same as tirzepatide?
Compounded tirzepatide usually contains the same active molecule, but it is not the same product as FDA-approved tirzepatide. Mounjaro and Zepbound go through FDA review for safety, effectiveness, and manufacturing quality, while compounded versions do not. Compounded vials may also differ in strength, ingredients, and purity.
Can I still get compounded tirzepatide in the US?
Large-scale compounding of tirzepatide is no longer permitted because the FDA removed the drug from its shortage list in late 2024 and set compliance deadlines in early 2025. Some pharmacies may still prepare patient-specific prescriptions under state rules, so availability varies by state and pharmacy. Enforcement actions have continued against compounders that produce copies of the brand-name drug.
Is compounded tirzepatide cheaper than Zepbound?
Compounded tirzepatide has often cost less per month than brand-name pens, but lower-cost self-pay vials from the manufacturer have narrowed that price gap. Compounded products are typically not covered by insurance, and manufacturer savings programs do not apply to them. Compare the total monthly cost, including syringes, shipping, and lab work, before deciding.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.